Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistOrganic Heirloom Plants was cited for marketing six products—including Sarracenia Purpurea, Breathe Rite H2O2 Therapy, Ivermectwin, Nature's Ancer, Zeolite, and Chaga Mushroom—as unapproved new drugs intended to cure, mitigate, treat, or prevent diseases, including mpox, in violation of sections 505(a) and 502 of the Federal Food, Drug, and Cosmetic Act. The company made disease claims on its website, Facebook page, and promotional literature without FDA approval or authorization, establishing the products as drugs under the Act. The FDA specifically requested cessation of sales for any unapproved products claiming to mitigate, prevent, treat, diagnose, or cure mpox, citing the declared nationwide public health emergency.